ARTICLE | Company News
Myriad Genetics Inc, Pathway Genomics diagnostic news
June 23, 2014 7:00 AM UTC
Myriad filed suit against Pathway in the U.S. District Court for the District of Utah, Central division alleging that Pathway’s BRCATrue gene test infringes 13 Myriad patents related to the breast cancer 1 early onset (BRCA1) and BRCA2 genes. The patents are U.S. Patent Nos. 5,709,999; 5,747,282; 5,753,441; 5,837,492; 6,033,857; 6,051,379; 6,951,721; 7,250,497; 7,470,510; 7,622,258; 7,838,237; 7,670,776; and 7,563,571. In a statement, Pathway said it does not infringe on any "valid patent claim." BRCATrue is a next-generation sequencing and deletion/duplication analysis assay that can detect mutations in the BRCA1 and BRCA2 genes. ...